1Lichtsteiner SP, Lebkowski JS, Vasserot AP. Telomerase, a target for anticancer therapy[J], Ann NY Acad Sci, 1999, 886:1-11.
2Dome JS, Look AT. Three molecular determinants of malignant conversion and their potential as therapeutic targets[J]. Curr Opin Oncol, 1999, 11:58 -67.
3Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization[J]. Cell, 1997,90(4): 785-795.
4Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells[J]. Science(Wash. DC), 1998,279:349-352.
5Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter[J]. Hum Mol Genet, 1999, 8:137 - 142.
6Kim NM, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer[J].Science(Wash. DC), 1994, 266:2011 - 2015.
7McKenzie KE, Umbricht CB, Sukumar S. Applications of telomerase research in the fight against cancer [ J ]. Mol Med Today, 1999, 5: 114-122.
8Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas[J]. Nat Genet, 1998, 18:65 -68.
9Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines[J]. Cancer Res,1985, 45:3668 - 3676.
10Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for trascriptional activation in immortalized amt cancer cells [ J ].Cancer Res, 1999, 59:551 - 557.
